Martin Treder, an expert in biotherapeutics, has been appointed chief scientific officer at Affimed NV, a Heidelberg, Germany-based company with a portfolio of bi- and tri-specific antibodies for cancer. Dr Treder joins Affimed from CT Atlantic AG in Switzerland where he was responsible for developing that company’s oncology pipeline.
Dr Treder graduated with honours from Monash University in Melbourne, Australia and obtained a diploma in biology at the University of Würzburg in Germany. He earned his PhD working in Axel Ullrich’s group at the Max Planck Institute of Biochemistry and received his doctorate from the Technical University of Munich.
Affimed announced the appointment on 20 January 2015.
Copyright 2015 Evernow Publishing Ltd